Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Thursday, January 17, 2013
Amgen today announced plans to build a new manufacturing facility in the Tuas Biomedical Park area of Singapore. Over the next several years, Amgen anticipates investing approximately $200 million to build an innovative new facility, which will ...
read more
Wednesday, December 06, 2017
Carmot and Amgen will work to select therapeutic targets and identify drug candidates.
read more
Monday, November 19, 2018
Amgen and Provention Bio announced a licensing and co-development agreement for AMG 714, identified by Provention as PRV-015.
read more
Wednesday, February 12, 2020
Amino GmbH announced plans to double production capacity by building a new facility at its Frellstedt, Germany location.
read more
Monday, November 12, 2012
AminoAcids.com is proud to announce the release of our newly validated B Vitamin Panel Analysis including Folic Acid for fresh/spent cell culture and fermentation media.
read more
Amneal Pharmaceuticals and Apiject Systems announced a strategic collaboration to expand domestic production of Apiject’s BFS-based injectable platform at Amneal’s Brookhaven, NY facility. The collaboration will enable large-scale capacity to produce...
read more
Tuesday, February 13, 2024
Amneal Pharmaceuticals, Inc announced that it has provided a Complete Response resubmission to the FDA for IPX203, a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules for the treatment of Parkinson’s disease (PD).
read more
Amneal has received FDA approval on its ANDA for Cyclophosphamide for Injection USP, the company's AP-rated therapeutic equivalent to Cytoxan 500 mg, 1 g and 2 g Single-Dose Vials.
read more
Wednesday, September 12, 2018
Amneal has received FDA approval on its ANDA for Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 mg and 200 mg and has immediately initiated commercialization activities.
read more
Amneal has received FDA approval on its ANDA for a generic version of Potassium Chloride oral solution and has immediately initiated commercialization activities.
read more
Amneal Pharmaceuticals announced a 10-year license and supply agreement for Levothyroxine sodium tablets with Jerome Stevens Pharmaceuticals.
read more
Wednesday, August 26, 2015
Amneal has announced the creation of Amneal Biosciences, a wholly-owned subsidiary of Amneal Pharmaceuticals LLC. Amneal Biosciences will focus exclusively on the commercialization of high-barrier-to-entry generic and specialty pharmaceuticals.
read more
Amneal announced a 5-year supply and distribution agreement with American Regent for the preservative-free generic alternative to Makena.
read more
Amneal Pharmaceuticals has announced a restructuring plan designed to reduce its cost base to and optimize its global manufacturing infrastructure.
read more
Amneal announced its Co-Founders, Chirag Patel and Chintu Patel, have been named Co-Chief Executive Officers, effective immediately.
read more